Compare · LHDX vs SLNO
LHDX vs SLNO
Side-by-side comparison of Lucira Health Inc. (LHDX) and Soleno Therapeutics Inc. (SLNO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LHDX and SLNO operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- SLNO is the larger of the two at $2.72B, about 13.2x LHDX ($206.3M).
- SLNO has hit the wire 9 times in the past 4 weeks while LHDX has been quiet.
- SLNO has more recent analyst coverage (12 ratings vs 0 for LHDX).
- Company
- Lucira Health Inc.
- Soleno Therapeutics Inc.
- Price
- $0.45-19.60%
- $52.72-0.18%
- Market cap
- $206.3M
- $2.72B
- 1M return
- -
- +65.79%
- 1Y return
- -
- -28.45%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2014
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 12
Lucira Health Inc.
Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.
Soleno Therapeutics Inc.
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Latest LHDX
- SEC Form 15-12G filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Bankruptcy or Receivership
- SEC Form NT 10-Q filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- SEC Form S-8 POS filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form NT 10-Q filed by Lucira Health Inc.
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits
- Lucira Health Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form NT 10-K filed by Lucira Health Inc.
Latest SLNO
- SEC Form SC 14D9 filed by Soleno Therapeutics Inc.
- SEC Form SC TO-T filed by Soleno Therapeutics Inc.
- Folia Health Launches "BRAVE-PWS" Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers
- SEC Form 8-K filed by Soleno Therapeutics Inc.
- SEC Form SC14D9C filed by Soleno Therapeutics Inc.
- SEC Form SC TO-C filed by Soleno Therapeutics Inc.
- Soleno Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
- SEC Form SC TO-C filed by Soleno Therapeutics Inc.
- Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
- SEC Form 4 filed by Manning Meredith